Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2017
Price : $35 *
At a glance
- Drugs Estradiol/dydrogesterone (Primary) ; Estradiol/dydrogesterone (Primary)
- Indications Cardiovascular disorders; Venous thromboembolism
- Focus Pharmacodynamics
- Acronyms OPTIMISE
- Sponsors Abbott Healthcare
- 31 Aug 2018 Biomarkers information updated
- 25 Oct 2015 Accrual to date is 80% according to United Kingdom Clinical Research Network record.
- 22 Oct 2015 Accrual to date is 78% according to United Kingdom Clinical Research Network record.